Streptococcus agalactiae UCN36 was resistant to lincomycin (MIC ‫؍‬ 16 g/ml) but susceptible to clindamycin (MIC ‫؍‬ 0.12 g/ml) and erythromycin (MIC ‫؍‬ 0.06 g/ml). 
Streptococcus agalactiae (group B streptococcus) is a major cause of invasive infection in neonates and pregnant women. It has also been increasingly recognized as a significant pathogen in nonpregnant adults, especially among patients with underlying conditions (13, 26) . S. agalactiae is responsible for acute and chronic diseases, such as respiratory tract infections, endocarditis, sepsis, meningitis, pyelonephritis, and neurological problems (12) . Penicillin G and ampicillin, which are always active against this pathogen, are the therapy of choice for S. agalactiae infections. However, in the case of intolerance to penicillins or lack of clinical response, clindamycin and macrolides are major alternatives (2) .
Lincosamide antibiotics include lincomycin and clindamycin. Their structure consists of a hygric acid alkylated in position 4 and linked to a 6 amino-thio-octopyranoside residue. Clindamycin is a semisynthetic derivative obtained by chlorination of lincomycin (4) . The spectrum of activity of lincosamides include gram-positive cocci, with some exceptions, such as Enterococcus faecalis (25) . They prevent the protein synthesis by inhibition of the peptidyltransferase in binding mainly the A2058 of the 23S rRNA in the 50S subunit of the bacterial ribosome (9) .
The most common mechanism of resistance to lincosamides involves N 6 dimethylation of a specific adenine residue (A2058) of the 23S rRNA molecule (17, 28) . This alteration of the antibiotic target site is invariably catalyzed by an rRNA methyltransferase encoded by erm genes. This resistance mechanism confers cross-resistance to macrolides, lincosamides, and streptogramin B (MLS phenotype) (17, 28) . In contrast to the MLS phenotype, specific resistance to lincosamides is due to enzymatic inactivation of those antibiotics. Phosphorylation and nucleotidylation of the hydroxyl group at position 3 of lincosamides have been detected in several species of Streptomyces (1, 21) . Lincosamide nucleotidyltransferases encoded by lnu genes (formerly lin) was observed in both animal and human strains (8, 10, 11, 18) . In clinical isolates, six lnu genes have been described: lnu(A), lnu(AЈ), lnu(B), lnu(B-like), lnu(A N2 ), and linF (3, 4, 5, 15, 27) . The O-nucleotidyltransferases encoded by these genes inactivate lincosamides by adenylylation (3, 5) . lnu(A) and lnu(AЈ) have been reported in Staphylococcus haemolyticus and Staphylococcus aureus, respectively (4, 5) . They encode two isoenzymes of 161 amino acids differing by 14 amino acids. An lnu(A N2 ) gene homologous to lnu(A) and lnu(AЈ) (55% of identity) was evidenced in Bacteroides spp. (27) (15) . In E. coli, the linF gene confers cross-resistance to lincomycin and clindamycin, whereas in the other organisms, the lnu genes confer resistance to lincomycin but not to clindamycin. However, the bactericidal activity of clindamycin, which is already weak against susceptible strains, is totally abolished (18) . In this study, we characterized the function and genetic support of a new lnu(C) gene that confers resistance to lincomycin in a clinical strain of S. agalactiae UCN36.
MATERIALS AND METHODS
Bacterial strains and growth conditions. S. agalactiae UCN36 was isolated in our laboratory from the vaginal tract of a pregnant woman. (3, 18) . E. coli AG100A, kindly provided by Hiroshi Nikaido was used in cloning experiments (23) . E. coli AG100A is a mutant susceptible to lincosamides resulting from inactivation of the AcrAB pump responsible for active efflux of lincosamides by transposon Tn903 harboring a kanamycin resistance gene. Strains were grown in brain heart infusion broth and agar incubated aerobically at 37°C. S. agalactiae BM132 was used as a negative control in lincosamide inactivation experiments (16) .
Antibiotic susceptibility testing. Susceptibility to antibiotics was determined by the disk diffusion technique (6) . MICs of antibiotics were determined by the agar dilution method with Mueller-Hinton medium supplemented with 5% sheep blood and incubated at 37°C under an aerobic atmosphere (6) . Erythromycin was from Aventis Pharma (Romainville, France). Lincomycin and clindamycin were from Pfizer (Groton, Conn.).
Lincosamide inactivation. The kinetics of lincomycin inactivation by resting cells were determined in liquid medium as previously described (19) . S. agalactiae UCN36 cells, suspended in 0.01 M phosphate buffer (pH 7) containing 14 g of lincomycin per ml, were incubated at 37°C for various periods of time. The pH of this suspension remained constant. Inactivation of lincomycin was followed by a bioassay with Micrococcus luteus ATCC 9341 as an indicator organism.
For preparation of modified lincomycin, E. coli AG100A cells containing the cloned lnu(C) gene were lysed by sonication. Cell debris were removed by centrifugation at 40,000 ϫ g for 45 min. Lincomycin (200 g/ml) was added in the supernatants and then incubated at 37°C for 18 h in the presence of ATP (2.5 mM) and MgCl 2 (50 mM). Inactivation of antibiotics was monitored as indicated above. Aliquots of inactivated lincomycin were freeze-dried.
Mass spectrometry. Samples were analyzed by using an electrospray ion trap mass spectrometer (LCQ Deca XP; Thermofinnigan, San Jose, CA) coupled on line with high-performance liquid chromatography (HPLC) (Surveyor LC). They were separated by reverse-phase HPLC on a C 18 capillary column (ThermoHyPurity C 18 150 by 0.18). A linear gradient (flow rate, 5 l/min) from 5 to 95% B was used, where solvent A was a 2 mM ammonium acetate aqueous solution and B was a 2 mM ammonium acetate solution in methanol. The electrospray ionization parameters were as follows: spray voltage, 4.5 kV; spray current, 80 A; sheath gas flow rate, 35; auxiliary gas flow rate, 10; capillary temperature, 250°C; capillary voltage, 10 V; tube lens offset, Ϫ5 V. These parameters were issued from an optimization of the detection of lincomycin. Spectra were acquired in a mode that alternated a full mass spectrometry (MS) scan (mass range from m/z 200 to 1,000; 3 microscans; maximum ion time, 100 ms), followed by a collisioninduced dissociation (CID)-MS2 and a CID-MS3 (3 microscans; maximum ion time, 400 ms; collision energy, 35%) of the most abundant ion detected in the previous spectra.
PCR conditions. The primers used for the amplification of lnu(A), lnu(AЈ), and lnu(B) genes were previously described (3, 18) . The PCR consisted of denaturation (95°C, 30 s), annealing (50°C, 30 s), and extension (72°C, 30 s to 3 min). The products were stored at 4°C until ready for analysis. The Taq DNA polymerase was obtained from Eurobio (Les Ulis, France).
Cloning and sequencing of a DNA fragment conferring resistance to lincosamides. Chromosomal DNA from S. agalactiae strain UCN36 was digested with various restriction enzymes and ligated at 4°C to plasmid vector pUC18 digested with the corresponding restriction enzymes. Recombinant plasmids were transformed by electroporation (Gene Pulser; Bio-Rad, Ivry-sur-Seine, France) into electrocompetent E. coli AG100A cells. E. coli AG100A transformants were selected on media containing clindamycin (6 g/ml), ampicillin (100 g/ml), and kanamycin (20 g/ml). Both DNA strands were sequenced in an automated ABI PRISM 377 DNA sequencer (Applied Biosystems, Foster City, CA). Nucleotide and amino acid sequences were analyzed by using the BLAST and FASTA software available at the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov/). Multiple-sequence alignments were performed with the ClustalX program available at the Centre de Ressources Infobiogen website (http://www.infobiogen.fr/).
Nucleotide sequence accession number. The nucleotide sequence of the 1,724-bp element from S. agalactiae UCN36 has been deposited in the GenBank database under accession no. AY928180.
RESULTS
Lincomycin resistance in S. agalactiae UCN36. S. agalactiae UCN36 displayed an unexpected phenotype of resistance to antibiotics. The strain was resistant to lincomycin (MIC ϭ 16 g/ml) but susceptible to erythromycin (MIC ϭ 0.06 g/ml), clindamycin (MIC ϭ 0.12 g/ml), quinupristin (MIC ϭ 16 g/ml), and dalfopristin (MIC ϭ 2 g/ml). This phenotype contrasted with the usual phenotype of cross-resistance between macrolides, lincosamides, and streptogramins B and was similar to the phenotype due to nucleotidylation of lincosamides conferred by the lnu class of genes in gram-positive cocci (3, 18) . However, PCR experiments failed to detect any DNA sequence related to lnu(A), lnu(AЈ), lnu(B), or lnu(Blike) genes.
To investigate the mechanism of resistance, a lincomycin inactivation bioassay was implemented. The kinetics of lincomycin inactivation by resting cells of S. agalactiae UCN36 showed that the concentration of native lincomycin (14 g/ml) decreased within 6 h to 2.5 g/ml, which is the limit of detection of the method in contrast to the negative-control S. agalactiae BM132. Clindamycin was similarly inactivated despite a low MIC. This result suggested the presence of a lincosamideinactivating enzyme in S. agalactiae UCN36.
Characterization and localization of the lnu(C) gene. Restricted DNA fragments from S. agalactiae UCN36 were cloned on plasmid pUC18, and recombinant plasmids were introduced into the lincosamide-sensitive E. coli mutant strain AG100A. The plasmid content of 10 transformants resistant to ampicillin, kanamycin, and clindamycin was analyzed by agarose gel electrophoresis of crude bacterial lysates. The smallest recombinant plasmid, pUV14, with a 4-kb HindIII insert was studied further. Acquisition of the recombinant plasmid by E. coli AG100A led to an increase in the MICs of clindamycin and lincomycin from 2 to 32 g/ml and 64 to 256 g/ml, respectively. The transformant was found able to inactivate lincomycin and clindamycin.
The insert was entirely sequenced. Analysis of the sequence revealed homology with known genes. The 5Ј end sequence of the insert was identical to that of a chromosomal fragment of S. agalactiae NEM316 bearing the 3Ј end of the cpsD gene and the first 272 nucleotides of the cpsE gene. The cpsD and cpsE genes belong to the capsular synthesis operon and encode two galactosyl transferases (14) . The open reading frame of the cpsE gene of S. agalactiae UCN36 was interrupted after nucleotide 272 by the insertion of a 1,724-bp fragment and continued after the insertion. As a consequence, the strain was nontypeable. Two open reading frames (ORFs) in the same orientation, ORF 1 and ORF 2 of 1,038 and 495 bp, respectively, were identified within the inserted fragment (Fig. 1) . Both translation ATG start codons were preceded at 9 bp by ribosome binding site-like sequences, 5Ј-CCGAAGGAGG-3Ј and 5Ј-TTTCTGGAGA-3Ј, complementary at 7 and 4 bases (underlined) to the 3Ј-OH-terminal (5Ј-UCUUUCCUCC-3Ј) sequence of Bacillus subtilis 16S rRNA, respectively (22) .
The deduced amino acid sequence (164 amino acids) obtained from ORF 2 showed 26 to 27% of identity with lincosamide nucleotidyltransferases, including LnuA N2 from Bacteroides sp. and LnuA and LnuAЈ from staphylococci. The lnurelated gene of S. agalactiae UCN36 was thus designated and 33 to 42% identity with putative transposases reported for Clostridium sordellii, Clostridium tetani, and Clostridium acetobutylicum (GenBank accession numbers BAC57548.1, NP_782873.1, and NP_348122.1, respectively). A conserved domain shared with transposases belonging to the IS1 family was detected between amino acid 52 and amino acid 126. The 1,724-bp fragment bearing ORF 1 and lnu(C) was bound at both extremities by 25-bp imperfect inverted repeats. Twenty-two nucleotides of 25 were complementary (Fig. 1) . This organization suggested that lnu(C) was borne by a transposon-like structure. The element was flanked by an AT-rich 8-bp sequence which could correspond to the duplication of the target during transposition.
Mechanism of resistance to lincosamides. Inactivation of 200 g of lincomycin per ml was obtained when crude extracts of E. coli AG100A/pUV14 were incubated with ATP and MgCl 2 but not when cells were incubated in the absence of ATP. HPLC analysis of the treated samples revealed a single peak eluted at 8.6 min. MS analysis of this fraction revealed three major peaks, displaying m/z of 736.4, 369.4, and 758.3. These 3 peaks corresponded to a unique 736.4-atomic mass unit (amu) compound and to its doubly charged and sodium adduct forms, respectively. The mass observed for this compound was in agreement with adenylylation of lincomycin (ϩ329). The structure of this compound was further characterized by CID-tandem mass spectrometry of both the singly and the doubly charged forms (Fig. 2) . Spectra revealed major fragments at 601 and 136 amu, resulting from leakage of the adenine moiety of the compound, and fragments at 469 and 268 amu, resulting from the leakage of the adenosine moiety.
DISCUSSION
Isolated resistance to lincosamides which defines the L phenotype, appears to be rare in S. agalactiae. Recently, S. agalactiae isolates intermediate or resistant to clindamycin and lincomycin but susceptible to erythromycin have been reported from New Zealand (20) . However, resistance to lincosamides was combined with high MICs of dalfopristin (4 to 32 g/ml), a streptogramin A antibiotic, defining the so-called LSA phenotype. The biochemical and genetic basis for this resistance remained unknown. In Canada, a single clindamycin-resistant and erythromycin-susceptible strain has been reported which contained an lnu(B) [lin(B)] gene similar to that initially reported for E. faecium and responsible for lincosamide nucleotidylation (3, 7) . In this study, we report a new lincosamide resistance gene called lnu(C) distantly related to the other lnu genes. Mass spectrometry experiments showed that lincomycin resistance was due to nucleotidylation of the antibiotic. The precise site of nucleotidylation of lincomycin and clindamycin was not characterized in this study. The LnuA nucleotidyltransferase modifies a hydroxyl group of clindamycin and lincomycin at positions 3 and 4, respectively. By contrast, LnuB modifies a hydroxyl at position 3 in both clindamycin and lincomycin.
In the original gram-positive host and in the E. coli transformant, both lincomycin and clindamycin were inactivated. However, resistance to lincomycin only was detected in S. agalactiae and resistance to both lincomycin and clindamycin was detected in E. coli. The reason for the difference in phenotypic expression of the resistance determinant in the two backgrounds remains unexplained. Hypothetically, the difference between the two lincosamides, which was also reported for the lnu(A) gene, might be related to differences in relative affinities of clindamycin and lincomycin for the ribosomes of gram-positive and gram-negative organisms and for the LnuC enzyme: clindamycin might have better affinity for the grampositive ribosomes than for LnuC.
The lnu(C) gene was located on a genetic element which bore a homologue of the IS1 transposase gene and which was delineated by imperfect inverted repeats. The structure of the genetic element displayed characteristics similar to those of a transposon. However, it differed from the classical insertion sequences, which are small and compact DNA sequences encoding only functions involved in their translocation, and from the classical transposons, which contain resolvase genes. Further characterization of this putative transposon is currently in progress. On a practical point of view, lincomycin resistance may be misidentified in strains with the L phenotype if only erythromycin is tested. In addition, the test of clindamycin does not predict for lincomycin resistance. Although the activity of clindamycin against S. agalactiae is only weakly affected by the mechanism of resistance, a 100-fold increase in the bacterial inoculum led to a 3-dilution increase in the MIC of clindamycin for S. agalactiae UCN36 (data not shown). This inoculum effect was greater than that observed for the lincosamide-susceptible strain, and the clinical significance of this modest increase in the MIC of clindamycin remains to be evaluated.
